Author

M. Dupre

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 3 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

J. Chamot-Rooke· 3 shared J. S. Dhenin· 2 shared A. Boquoi· 1 shared A. K. Buell· 1 shared A. Krick· 1 shared C. Mauriac· 1 shared D. Borges Lima· 1 shared F. Platten· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

J. Chamot-Rooke

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A multi-parameter optimization in middle-down analysis of monoclonal antibodies by LC-MS/MS

J. S. Dhenin, M. Dupre, K. Druart, A. Krick, C. Mauriac, J. Chamot-Rooke

This paper optimizes parameters for middle-down analysis of monoclonal antibodies using LC-MS/MS to improve sequence coverage.

bioRxiv · Dec 8, 2022Biochemistry

TDFragMapper: a visualization tool for evaluating experimental parameters in top-down proteomics

J. S. Dhenin, D. Borges Lima, M. Dupre, J. Chamot-Rooke

TDFragMapper evaluates experimental parameters in top-down proteomics by visualizing fragment ions and sequence coverage.

Bioinformatics · Nov 18, 2021Peer-reviewedBiochemistry

Universal amyloidogenicity of patient-derivedimmunoglobulin light chains

R. Sternke-Hoffmann, T. Pauly, R. K. Norrild, J. Hansen, M. Dupre, F. Tucholski, M. Duchateau, M. Rey, S. Metzger, A. Boquoi, F. Platten, S. U. Egelhaaf, J. Chamot-Rooke, R. Fenk, L. Nagel-Steger, , A. K. Buell

This study shows that all tested patient-derived immunoglobulin light chains have comparable amyloidogenic potential, with proteolytic cleavage being a key determinant of in vivo aggregation.

bioRxiv · May 12, 2021 · PreprintBiophysics